Louisiana HCR120 establishes the PACE Task Force to study GLP-1 medications' clinical history, accessibility, and insurance costs.
Louisiana HCR120 creates the PACE Task Force to study GLP-1 medications, focusing on their clinical history, accessibility, and insurance costs. The task force will consider topics such as pricing differences for diabetes versus weight loss, the impact on insurer risk pools, and cost-effectiveness. The task force will include representatives from the Louisiana Department of Insurance, the Louisiana Association of Health Plans, the Louisiana Department of Health, and the Louisiana Board of Pharmacy, as well as a healthcare provider specializing in endocrinology or obesity.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.